Diabetes and Vascular Disease Research · 2022 · 14 citations · 35 references
Life SciencesBioinformaticsEndocrinologyDiabetologyMass Spectrometric AnalysisProteomicsClinical ProteomicsDiabetes MellitusGlucagon-like Peptide-1 Receptor AgonistsMass Spectrometry Data AnalysisMass Spectrometry-based ProteomicsProteomic ProfilingFold Change AnalysisGlucagon-like Peptide 1 Receptor AgonismGlucagon-like PeptidesMaldi-tof Mass SpectrometryMass Spectrometry ProteomicsMass Spectrometry-based Protein IdentificationPlasma ProteomicsProteomic Data Analysis
Background Diabetes mellitus is a chronic multisystem disease with a high global prevalence, including in Saudi Arabia. The Glucagon-like Peptide (GLP-1) receptor agonist liraglutide is known to lower glucose levels, reduce weight and improve cardiovascular outcome. However, mechanisms underlying the benefits of liraglutide treatment in patients with type 2 diabetes mellitus (T2DM) remain unclear. Methods In the present study, a 2D-DIGE MALDI-TOF mass spectrometric approach combined with bioinformatics and network pathway analysis explore the plasma proteomic profile. The study involved 20 patients with T2DM with mean age of 54.4 ± 9.5 years and Hemoglobin A1c (HbA1c) between 8% and 11% (inclusive). Results A statistically significant change ( p < .006) was observed in HbA1c with no significant changes in body weight, renal function, or markers of dyslipidemia post-treatment with liraglutide. 2 D-DIGE gel analysis identified significant changes (⩾1.5-fold change, Analysis of variance (ANOVA), p ⩽ 0.05) in 72 proteins, (62 down and 10 up) in liraglutide pre-treatment compared to the post-treatment state. Proteins identified in our study were found to regulate metabolic processes including acute phase response proteins, enzymes, apolipoproteins with involvement of the inflammatory signaling pathways, NF-κB, AKT, and p38 MAPK Conclusion Liraglutide treatment decreased levels of acute phase response that to reduce the systemic chronic inflammatory state and oxidative stress, and eventually improve the cardio-metabolic profile in these patients.
35
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer, Brian Claggett, Rafael Díaz et al. · New England Journal of Medicine · 2015 · 2.3K citations · Full text
Medicine, Cardiology, Pharmacology +17